Prescient launches capital raise to progress pipeline of cancer therapies
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan...
We think that it's fair to say that the possibility of finding fantastic multi-year winners...
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum...
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell...
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.